Live price temporarily unavailable.
SAB Biotherapeutics (SABS) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $55.2M | $60.9M | $23.9M | $2.24M | $1.32M | $0 |
| Growth (year over year) | — | +10.2% | −60.7% | −90.6% | −40.9% | −100.0% |
| Operating income | $20.6M | −$13.4M | −$28.9M | −$38.1M | −$42.9M | −$49.0M |
| Operating margin | 37.2% | −22.0% | −121.0% | −1700.6% | −3244.9% | — |
| Net income | $20.1M | −$17.1M | −$18.7M | −$42.2M | −$34.1M | $13.3M |
| Net margin | 36.4% | −28.2% | −78.4% | −1884.5% | −2579.0% | — |
| EPS (diluted) | $7.40 | −$6.30 | −$4.31 | −$7.64 | −$3.68 | −$0.79 |
| Balance sheet | ||||||
| Cash and equivalents | $12.6M | $33.2M | $15.0M | $56.6M | $8.90M | $10.5M |
| Total assets | $56.5M | $81.1M | $50.9M | $83.9M | $44.2M | $172.8M |
| Total liabilities | $17.5M | $42.6M | $19.8M | $26.6M | $18.2M | $21.3M |
| Shareholders' equity | $39.0M | $38.5M | $31.1M | $57.3M | $26.0M | $151.5M |
| Cash flow | ||||||
| Operating cash flow | $10.0M | $1.99M | −$23.5M | −$25.1M | −$34.3M | −$44.8M |
| Capital expenditure | $12.7M | $10.9M | $2.17M | $197.2K | $337.3K | $933.2K |
| Free cash flow | −$2.73M | −$8.96M | −$25.6M | −$25.3M | −$34.6M | −$45.7M |
| Q3 FY24†Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | — | — | — | — | — | — |
| Growth (year over year) | −100.0% | — | — | — | — | — | — | — |
| Operating income | −$11.3M | — | −$10.8M | −$9.73M | −$12.7M | −$15.8M | −$20.0M | −$23.4M |
| Net income | −$10.3M | — | −$5.20M | −$10.1M | $45.4M | −$16.9M | −$18.9M | −$22.5M |
| EPS (diluted) | −$1.12 | — | −$0.56 | −$1.09 | −$0.21 | $1.07 | −$0.35 | −$0.28 |
| Balance sheet | ||||||||
| Cash and equivalents | $9.17M | $8.90M | $5.64M | $3.69M | $29.4M | $10.5M | $20.5M | $8.27M |
| Total assets | $53.8M | $44.2M | $38.1M | $30.1M | $183.4M | $172.8M | $248.5M | $238.2M |
| Total liabilities | $16.9M | $18.2M | $16.7M | $18.1M | $18.4M | $21.3M | $21.2M | $23.4M |
| Shareholders' equity | $36.9M | $26.0M | $21.4M | $12.0M | $165.1M | $151.5M | $227.2M | $214.8M |
| Cash flow | ||||||||
| Operating cash flow | −$6.29M | — | −$7.80M | −$7.15M | −$13.0M | −$16.8M | −$14.3M | −$9.84M |
| Capital expenditure | $100.3K | — | — | — | — | — | $983.3K | $1.59M |
| Free cash flow | −$6.39M | — | — | — | — | — | −$15.3M | −$11.4M |
From SAB Biotherapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning SAB Biotherapeutics in our feed yet.